Roivant Sciences (ROIV) investor relations material

Executive summary

• Commercial preparations for brepocitinib in dermatomyositis are on track for launch by end of September 2026, with multiple late-stage clinical programs progressing and commercial teams ready.

• Advanced pivotal studies for IMVT-1402 and mosliciguat, with key topline data expected in the second half of 2026.

• Received $950 million from Moderna in July 2026 as part of a global patent settlement, with up to $1.3 billion additional contingent on litigation outcome; new international lawsuits filed against Pfizer and BioNTech.

• Expanded pipeline with new indications and converted multiple proof-of-concept studies into pivotal programs.

• Maintains strong liquidity with $3.9 billion in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026, excluding the Moderna payment.

Financial highlights

• R&D expenses for the quarter were $202 million, up from $152.9 million year-over-year.

• G&A expenses were $166 million (GAAP) and $91 million (non-GAAP), with increases driven by employee bonuses and payroll taxes related to the Moderna settlement.

• Net loss was $290.6 million for the quarter ended June 30, 2026; non-GAAP net loss was $243.7 million.

• Cash, cash equivalents, and marketable securities totaled $3.9 billion as of June 30, 2026, excluding the $950 million Moderna payment received in July.

• Repurchased 7.3 million common shares for $208.7 million during the quarter.

Outlook and guidance

• Commercial launch of brepocitinib in dermatomyositis expected by end of September 2026, with a "slow and steady" approach and patient support teams ready.

• Multiple pivotal and proof-of-concept study readouts expected in the second half of 2026, including for brepocitinib, IMVT-1402, and mosliciguat.

• NDA/BLA filings and commercial launches across 7+ indications anticipated by end of 2028.

• Cash runway projected to support operations into profitability.

• Additional updates expected on D2T RA, PH-ILD, CLE, and Graves’ disease programs in the second half of 2026 and into 2027.